Analytical Data
-
Gene name
WEE1
- Application
-
Alternative Names
WEE1；Wee1-like Protein kinase
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P30291
-
Expression Region
215-646aa
-
AA Sequence
DTEKSGKRE FDVRQTPQVN INPFTPDSLL LHSSGQCRRR KRTYWNDSCG EDMEASDYEL EDETRPAKRI TITESNMKSR YTTEFHELEK IGSGEFGSVF KCVKRLDGCI YAIKRSKKPL AGSVDEQNAL REVYAHAVLG QHSHVVRYFS AWAEDDHMLI QNEYCNGGSL ADAISENYRI MSYFKEAELK DLLLQVGRGL RYIHSMSLVH MDIKPSNIFI SRTSIPNAAS EEGDEDDWAS NKVMFKIGDL GHVTRISSPQ VEEGDSRFLA NEVLQENYTH LPKADIFALA LTVVCAAGAE PLPRNGDQWH EIRQGRLPRI PQVLSQEFTE LLKVMIHPDP ERRPSAMALV KHSVLLSASR KSAEQLRIEL NAEKFKNSLL QKELKKAQMA KAAAEERALF TDRMATRSTT QSNRTSRLIG KKMNRSVSLT IY
-
Molecular Weight
75 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
WEE1 is a pivotal kinase that plays a critical role in regulating the cell cycle, particularly in coordinating DNA damage responses and ensuring genomic stability. It functions primarily by inhibiting cyclin-dependent kinases (CDKs), which are essential for the transition from the G2 phase to mitosis. In the context of cancer research, WEE1 has garnered significant attention due to its potential as a therapeutic target; many cancer cells exhibit aberrant cell cycle regulation and heightened sensitivity to DNA damage. Research has shown that inhibiting WEE1 can sensitize these cells to conventional therapies, such as radiation and chemotherapy, leading to enhanced anti-tumor effects. The development of WEE1 inhibitors, like AZD1775, has been a focal point in clinical trials, aiming to improve patient outcomes in various cancers, including ovarian and breast cancer. Furthermore, the exploration of WEE1's role in different tumor types and its interaction with other cellular pathways continues to enhance our understanding of tumor biology and therapy resistance. Ultimately, ongoing research into WEE1 recombinant proteins aims to elucidate their precise mechanisms of action in cell cycle regulation and therapeutic responses, offering promising avenues for targeted cancer treatments.
